[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441056":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":61,"collaborators":18,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":18,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":18,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Ente Ospedaliero Cantonale, Bellinzona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexamethasone group","EXPERIMENTAL","Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis",[13],"Drug: Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg\u002Fml)",{"label":15,"type":16,"description":17,"interventionNames":18},"Routine care","NO_INTERVENTION","In this group only routinely performed anaesthesia protocol will be provided",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg\u002Fml)","Dexamethasone will be administered as an injectable solution (4mg\u002Fml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)",[9],[26],"Mephameson",[28],{"name":29,"affiliation":30,"role":31},"Christian MD Candrian, Prof.","EOC","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","0041918117029","Gabriela.Induni-Lang@eoc.ch",{"name":38,"role":34,"phone":35,"phoneExt":18,"email":36},"Gabriela Induni-Lang",[40],{"facility":41,"status":42,"city":43,"state":18,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Christian Candrian","RECRUITING","Lugano","6900","Switzerland","CH",{"type":48,"coordinates":49},"Point",[50,51],8.96004,46.01008,{"lat":51,"lon":50},[54,58],{"name":55,"role":34,"phone":56,"phoneExt":18,"email":57},"Christian Candrian, Prof.Dr.med","+41 (0) 91 811 61 23","christian.candrian@eoc.ch",{"name":59,"role":34,"phone":18,"phoneExt":18,"email":60},"Gianluigi Capone, Dr.","gianluigi.capone@eoc.ch",{"type":31,"investigatorFullName":41,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator","100441056","phase-4-this-is-a-study-to-verify-if-periarticular-hip-injection-of-corticosteroid-after-hip-replacement-reduce-the-pain-and-the-hospitalisation-time-100441056",false,"NCT05023369","This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time","Periarticular Administration of Dexamethasone to Improve Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications in Patients Undergoing Hip Arthroplasty - A Randomized Trial","Inclusion Criteria:\n\n* Patients undergoing unilateral cemented hip endoprosthesis for femoral neck fracture\n* Patients aged 50-90 years old\n* Patients with a BMI \\>18.5 and \\\u003C35\n* Patients able to provide informed consent and follow all the study procedures as indicated by the protocol\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* Contraindications to steroids\n* Revision endoprosthesis\n* Active steroid or immunosuppressive therapy in the last 30 days before the operation\n* Pregnant or breast-feeding women\n* Presence of other clinically significant concomitant disease states (ASA IV)\n* Uncontrolled diabetes mellitus\n* Contraindications to NSAIDs\n* Chronic systemic diseases as immunodeficiency, autoimmune disease (Systemic Lupus Erythematosus, SLE), gout, rheumatic arthritis\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.","ALL","50 Years","90 Years",{"count":74,"type":75},110,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The investigators are going to evaluate if periarticular corticosteroid injection during endoprothesis implantation can lead to any advantage to the patients, namely if it can reduce post-operative pain, lenght and cost of hospitalisation, use of analgesics drugs.",[81],"Femoral Neck Fractures","2026-03-03",{"date":84,"type":85},"2026-03-05","ACTUAL",{"date":87,"type":85},"2021-12-10",{"date":89,"type":75},"2026-11-01",{"name":5,"class":6},1]